Clinical Trial Update: Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)

View source ↗

Summary

This announces a pre-approval single-patient expanded-access program for talazoparib (PF-06944076) in a patient with metastatic castration-resistant prostate ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Talzenna (talazoparib)

Snippet

Sponsor: Pfizer | Conditions: Metastatic Castration-Resistant Prostate Cancer | Status: AVAILABLE